Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs

Question 361: Oximes are a mainstay of treatment in toxicology. All of the following poisonings are indications for using oximes, EXCEPT:

A. Organophosphate insecticide (Tik20)
B. Baygon (Propoxur) (Correct Answer)
C. Malathion
D. Parathion

Explanation: ### Explanation The core concept here is the difference between **Organophosphates (OP)** and **Carbamates** in their interaction with the enzyme Acetylcholinesterase (AChE). **1. Why Baygon (Propoxur) is the Correct Answer:** Baygon is a **Carbamate**. Unlike Organophosphates, carbamates cause **reversible** inhibition of AChE. The carbamoyl-enzyme complex dissociates spontaneously and rapidly (usually within minutes to hours). Furthermore, carbamates do not undergo "aging" (the permanent covalent bonding seen in OP poisoning). * **Contraindication:** Oximes (like Pralidoxime) are generally **avoided** in carbamate poisoning because they are unnecessary and may actually inhibit AChE further, potentially worsening the toxicity (especially in Carbaryl poisoning). **2. Why the other options are incorrect:** * **Malathion and Parathion (Options C & D):** These are classic Organophosphates. They cause irreversible inhibition of AChE by phosphorylating the enzyme. Oximes are essential here to "rescue" the enzyme before "aging" occurs. * **Tik-20 (Option A):** This is a common brand name for an Organophosphate insecticide (often containing Malathion or Fenitrothion). As an OP compound, it is a primary indication for oxime therapy. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Oximes:** They act as "Cholinesterase Reactivators" by displacing the phosphate group from the enzyme, but only **before aging** occurs. * **Aging:** Once the enzyme-phosphate bond matures (aging), oximes are ineffective. This is why they must be given early (ideally within 24–48 hours). * **Atropine vs. Oximes:** Atropine is the physiological antidote (blocks muscarinic receptors) for **both** OP and Carbamates. Oximes are the specific biochemical antidote for **OP only**. * **Mnemonic:** "Oximes for Organophosphates" (Both start with 'O'). Avoid Oximes for Carbamates (except in rare mixed poisonings).

Question 362: Which antibiotic can accentuate the neuromuscular blockade produced by d-tubocurarine?

A. Penicillin G
B. Erythromycin
C. Streptomycin (Correct Answer)
D. Chloramphenicol

Explanation: **Explanation:** The correct answer is **Streptomycin**. **Mechanism of Interaction:** Aminoglycoside antibiotics (like Streptomycin, Gentamicin, and Neomycin) possess a known side effect of neuromuscular blockade. They interfere with neuromuscular transmission by two primary mechanisms: 1. **Inhibition of Acetylcholine (ACh) release:** They compete with Calcium ions at the pre-junctional nerve terminal, reducing the amount of ACh released. 2. **Post-junctional sensitivity:** They decrease the sensitivity of the motor end-plate to ACh. When administered with non-depolarizing neuromuscular blockers like **d-tubocurarine**, these effects are additive, leading to prolonged respiratory paralysis or "apnea." **Analysis of Incorrect Options:** * **A. Penicillin G:** A cell-wall synthesis inhibitor (Beta-lactam) that does not interfere with calcium channels or ACh release; it has no effect on the neuromuscular junction. * **B. Erythromycin:** A Macrolide that inhibits protein synthesis (50S subunit). While it can interact with drugs via CYP3A4 inhibition, it does not potentiate neuromuscular blockade. * **D. Chloramphenicol:** Another protein synthesis inhibitor (50S subunit) primarily associated with bone marrow suppression and Gray Baby Syndrome, but not neuromuscular interference. **High-Yield Clinical Pearls for NEET-PG:** * **Order of Potency:** Among aminoglycosides, the neuromuscular blocking potency is: **Neomycin > Streptomycin > Amikacin > Gentamicin.** * **Management:** Aminoglycoside-induced blockade can be partially reversed by **Intravenous Calcium Gluconate** (which overcomes the pre-junctional calcium competition) and Neostigmine. * **Contraindication:** Aminoglycosides should be used with extreme caution in patients with **Myasthenia Gravis** as they can precipitate a myasthenic crisis.

Question 363: A patient on indinavir treatment presents with jaundice. Detailed evaluation reveals that the elevated bilirubin is mainly the indirect fraction. What is the probable mechanism of indirect hyperbilirubinemia in this setting?

A. Increased bilirubin production
B. Decreased hepatocellular uptake
C. Decreased conjugation (Correct Answer)
D. Hemolysis

Explanation: ### Explanation **Correct Option: C. Decreased conjugation** Indinavir, a Protease Inhibitor (PI) used in HIV treatment, is well-known to cause asymptomatic **indirect (unconjugated) hyperbilirubinemia**. The underlying mechanism is the **potent inhibition of Uridine diphosphate-glucuronosyltransferase (UGT1A1)**, the enzyme responsible for conjugating bilirubin in the liver. This mimics the clinical presentation of **Gilbert Syndrome**. Since the bilirubin cannot be conjugated, it remains in the indirect form, leading to jaundice without significant elevation of transaminases or alkaline phosphatase. **Analysis of Incorrect Options:** * **A. Increased bilirubin production:** This typically occurs in states of massive cell turnover or ineffective erythropoiesis, which is not the mechanism for indinavir-induced jaundice. * **B. Decreased hepatocellular uptake:** While some drugs (like Rifampicin) can interfere with the uptake of bilirubin into hepatocytes via OATP transporters, Indinavir specifically targets the enzymatic conjugation step. * **D. Hemolysis:** Although hemolysis causes indirect hyperbilirubinemia, Indinavir does not typically cause red cell breakdown. In hemolysis, you would also expect low haptoglobin and elevated LDH, which are absent here. **High-Yield Clinical Pearls for NEET-PG:** * **Indinavir Side Effects:** Remember the triad: **Indirect Hyperbilirubinemia**, **Nephrolithiasis** (crystalluria—patients must stay hydrated), and **Lipodystrophy** (buffalo hump/insulin resistance). * **Atazanavir:** Another Protease Inhibitor that frequently causes indirect hyperbilirubinemia via the same UGT1A1 inhibition mechanism. * **Gilbert Syndrome Link:** Patients with pre-existing Gilbert Syndrome are at a much higher risk of developing visible jaundice when started on Indinavir or Atazanavir.

Question 364: What is the primary purpose of pharmacovigilance?

A. To monitor drug toxicity (Correct Answer)
B. To monitor unauthorized drug manufacture
C. Monitoring of students
D. To check drug costs

Explanation: **Explanation:** **Pharmacovigilance (PV)** is defined by the WHO as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems [1]. **Why Option A is correct:** The primary goal of pharmacovigilance is to ensure patient safety by monitoring the **toxicity** and safety profile of drugs after they have been released into the market (Phase IV: Post-marketing surveillance) [1], [2]. Since clinical trials involve a limited number of participants, rare or long-term adverse drug reactions (ADRs) often only surface when the drug is used by the general population [1]. PV systems identify these "signals" to update drug labels or, if necessary, withdraw dangerous drugs from the market [2]. **Why other options are incorrect:** * **Option B:** Monitoring unauthorized manufacture is a regulatory and legal function (Drug Controller General of India/FDA), not a clinical pharmacology function. * **Option C:** Monitoring students is an academic/administrative task unrelated to drug safety. * **Option D:** Drug cost monitoring (Pharmacoeconomics) deals with the cost-benefit analysis of therapy, not the clinical safety of the molecule. **High-Yield Clinical Pearls for NEET-PG:** * **Phase IV Clinical Trial:** This is the phase synonymous with pharmacovigilance. * **Pharmacovigilance Programme of India (PvPI):** Launched in 2010; the National Coordinating Centre is the **Indian Pharmacopoeia Commission (IPC)**, Ghaziabad. * **Uppsala Monitoring Centre (UMC):** Located in Sweden, it is the WHO's international hub for ADR monitoring. * **Yellow Card Scheme:** A famous ADR reporting system used in the UK (often asked in international context).

Question 365: Which drug should be avoided in a patient with a known allergy to penicillin?

A. Sulphonamide
B. Tetracycline
C. Ampicillin (Correct Answer)
D. Chloramphenicol

Explanation: **Explanation:** The correct answer is **Ampicillin** because it belongs to the **Penicillin group** of antibiotics. **1. Why Ampicillin is the Correct Choice:** Ampicillin is a semi-synthetic, broad-spectrum penicillin. All drugs within the penicillin class share a common **6-aminopenicillanic acid** nucleus and a **Beta-lactam ring**. If a patient is allergic to penicillin, they are hypersensitive to this core structure. Administering Ampicillin would trigger a cross-reactivity reaction, ranging from a mild skin rash to life-threatening **Type I hypersensitivity (Anaphylaxis)**. **2. Why Other Options are Incorrect:** * **Sulphonamides (A):** These are synthetic bacteriostatic agents (e.g., Sulfamethoxazole). While they are common allergens, they do not share structural similarity with the Beta-lactam ring. * **Tetracycline (B):** This is a protein synthesis inhibitor (30S subunit). It is chemically distinct from penicillins and is safe to use in penicillin-allergic patients. * **Chloramphenicol (D):** This is a broad-spectrum antibiotic that inhibits the 50S ribosomal subunit. It does not cross-react with penicillins. **3. Clinical Pearls for NEET-PG:** * **Cross-Reactivity with Cephalosporins:** Patients with a penicillin allergy have a **3–10% risk** of cross-reactivity with first-generation cephalosporins (e.g., Cephalexin). The risk is much lower with third-generation agents (e.g., Ceftriaxone). * **Safe Alternatives:** For Gram-positive infections in penicillin-allergic patients, **Macrolides** (Erythromycin/Azithromycin) or **Clindamycin** are often the drugs of choice. * **Monobactams:** **Aztreonam** is the only Beta-lactam that generally does *not* cross-react with penicillins (except for a specific cross-sensitivity with Ceftazidime).

Question 366: Which of the following drugs, when administered in high doses, can cause convulsions?

A. Penicillin (Correct Answer)
B. Aminoglycosides
C. Erythromycin
D. All of the above

Explanation: **Explanation:** **1. Why Penicillin is the Correct Answer:** High doses of Penicillins, particularly **Penicillin G**, are well-known to be neurotoxic. The underlying mechanism is the **antagonism of GABA-A receptors** in the central nervous system. Since GABA is the primary inhibitory neurotransmitter, its blockade leads to neuronal hyperexcitability, which can manifest as myoclonus or generalized tonic-clonic **convulsions**. This risk is significantly increased in patients with **renal failure** (due to drug accumulation) or those with pre-existing seizure disorders. **2. Why Other Options are Incorrect:** * **Aminoglycosides (e.g., Gentamicin):** These are primarily associated with **ototoxicity** (vestibular and cochlear damage) and **nephrotoxicity** (acute tubular necrosis). They do not typically cause CNS excitation or seizures. * **Erythromycin (Macrolide):** The hallmark adverse effects of Macrolides include GI upset, **cholestatic jaundice** (especially with Erythromycin estolate), and **QT interval prolongation**. They are not associated with convulsions. **3. High-Yield Clinical Pearls for NEET-PG:** * **Other Antibiotics causing Seizures:** Apart from Penicillins, **Imipenem** (a Carbapenem) and **Fluoroquinolones** (e.g., Ciprofloxacin) are high-yield causes of drug-induced seizures. * **Imipenem vs. Meropenem:** Imipenem has a higher seizure potential than Meropenem; hence Meropenem is preferred in CNS infections like meningitis. * **Ceftriaxone:** While most Beta-lactams can cause seizures at very high doses, Ceftriaxone is more commonly noted for causing **biliary sludge** (pseudolithiasis). * **Management:** Drug-induced seizures are generally managed by discontinuing the offending agent and administering **Benzodiazepines**.

Question 367: All of the following statements are true regarding warfarin toxicity (skin necrosis) except?

A. Skin necrosis occurs during the initiation of therapy.
B. Most common sites are toes and tips of fingers. (Correct Answer)
C. Decreased quantity of protein C.
D. Decreased incidence of adverse effects if therapy with LMWH is started.

Explanation: **Explanation:** **Warfarin-Induced Skin Necrosis (WISN)** is a rare but serious complication occurring due to a transient hypercoagulable state during the initiation of therapy. **Why Option B is the Correct Answer (The False Statement):** The most common sites for skin necrosis are areas with **abundant subcutaneous fat**, such as the **breasts, thighs, buttocks, and abdomen**. It is caused by microvascular thrombosis in the dermal capillaries. In contrast, "Purple Toe Syndrome" (a different warfarin complication) involves the toes, but true skin necrosis preferentially affects fatty tissues. **Analysis of Other Options:** * **Option A:** True. It typically occurs within **3–10 days** of starting therapy. * **Option C:** True. Warfarin inhibits Vitamin K-dependent factors (II, VII, IX, X) and anticoagulant proteins (Protein C and S). **Protein C has a shorter half-life** (~6 hours) than procoagulant factors like Factor II and X. Thus, Protein C levels drop rapidly, creating a temporary prothrombotic window. Patients with hereditary Protein C deficiency are at the highest risk. * **Option D:** True. Starting **LMWH or Unfractionated Heparin** as "bridge therapy" provides immediate anticoagulation, counteracting the transient hypercoagulability until the procoagulant factors are sufficiently depleted. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Rapid depletion of Protein C → Relative hypercoagulability → Microvascular thrombosis → Skin necrosis. * **Management:** Discontinue Warfarin, administer **Vitamin K**, and provide **Protein C concentrates** or Fresh Frozen Plasma (FFP). Continue Heparin for anticoagulation. * **Key Risk Factor:** Loading doses of Warfarin (e.g., >10mg) increase the risk of WISN.

Question 368: In which clinical trial phase are healthy human volunteers typically used?

A. Phase I (Correct Answer)
B. Phase II
C. Phase III
D. Phase IV

Explanation: The correct answer is **Phase I**. Clinical trials are conducted in a sequential manner to ensure drug safety and efficacy before and after market approval. **Why Phase I is correct:** Phase I is the first stage of testing a new drug in humans (First-in-human trials). It typically involves a small group (20–80) of **healthy human volunteers** [1]. The primary objective is to determine **safety, tolerability, and pharmacokinetics** (ADME) [1]. An exception occurs with highly toxic drugs, such as anti-cancer agents, where Phase I trials are conducted directly on patients. **Analysis of Incorrect Options:** * **Phase II (Therapeutic Exploratory):** This phase is conducted on a small group of **patients** (100–300) with the target disease [2]. Its primary goal is to assess **efficacy** and determine the optimal dose-range [2]. * **Phase III (Therapeutic Confirmatory):** This involves a large-scale multicentric study on thousands of **patients**. It aims to confirm efficacy, monitor side effects, and compare the drug with existing treatments (standard of care) or placebos. * **Phase IV (Post-Marketing Surveillance):** This occurs after the drug is approved and marketed. It monitors long-term safety and detects **rare adverse effects** in the general population. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0 (Microdosing):** Uses sub-therapeutic doses in humans to study pharmacokinetics; it does not replace Phase I. * **Maximum Tolerated Dose (MTD):** Identified during Phase I. * **Ceiling Effect:** Often identified during Phase II. * **Phase III** is the most expensive and time-consuming phase. * **Black Box Warnings** are usually a result of Phase IV data.

Question 369: Which of the following factors markedly increases the risk of valproate-induced liver toxicity?

A. Allergic reactions to phenobarbital
B. Male gender
C. Age younger than 2 years (Correct Answer)
D. Family history of epilepsy

Explanation: ### Explanation **Correct Option: C. Age younger than 2 years** Valproate-induced hepatotoxicity (idiosyncratic liver failure) is a rare but potentially fatal complication. The risk is significantly elevated in children **younger than 2 years of age**, especially when valproate is used as **polytherapy** (combined with other enzyme-inducing anti-epileptics). **Underlying Medical Concept:** In young children, the metabolic pathways for valproate are immature. Instead of normal glucuronidation, the drug undergoes increased ω-oxidation, leading to the formation of a toxic metabolite called **4-pentenoic acid** (and its derivatives). This metabolite inhibits mitochondrial beta-oxidation of fatty acids, resulting in microvesicular steatosis and hepatic necrosis. **Analysis of Incorrect Options:** * **A. Allergic reactions to phenobarbital:** While phenobarbital is an enzyme inducer that can increase the production of toxic valproate metabolites, a history of *allergy* to it does not physiologically predispose a patient to valproate-induced liver damage. * **B. Male gender:** Gender is not a recognized risk factor for valproate-induced hepatotoxicity. * **D. Family history of epilepsy:** While a family history of **metabolic disorders** (like Alpers-Huttenlocher syndrome or urea cycle defects) increases risk, a general family history of epilepsy does not. --- ### High-Yield NEET-PG Pearls * **The "Fatal Triad" for Valproate Hepatotoxicity:** Age < 2 years, Polytherapy, and underlying Metabolic/Mitochondrial disorders. [1] * **Metabolic Marker:** Elevated serum ammonia levels (Hyperammonemia) can occur even without overt liver failure due to interference with the urea cycle. * **Management:** Intravenous **L-carnitine** is the specific antidote for valproate-induced hepatotoxicity/encephalopathy as it helps restore mitochondrial fatty acid metabolism. * **Teratogenicity:** Valproate is highly associated with **Neural Tube Defects** (Spina Bifida) due to interference with folate metabolism. [1]

Question 370: Which of the following drugs is associated with teratogenic effects?

A. Amiodarone
B. Lithium (Correct Answer)
C. Valproate
D. Phenytoin

Explanation: **Explanation:** The correct answer is **Lithium**. While all four drugs listed are technically teratogenic, the context of NEET-PG questions often requires identifying the most characteristic or "classic" association for a specific clinical scenario. Lithium is famously associated with **Ebstein’s Anomaly**, a congenital heart defect characterized by the downward displacement of the tricuspid valve leaflets into the right ventricle ("atrialization" of the ventricle). **Analysis of Options:** * **Lithium (Correct):** Used for Bipolar Disorder. Exposure during the first trimester increases the risk of Ebstein’s Anomaly. * **Valproate:** While highly teratogenic, it is most specifically associated with **Neural Tube Defects** (e.g., Spina Bifida) due to interference with folate metabolism. * **Phenytoin:** Associated with **Fetal Hydantoin Syndrome**, characterized by craniofacial dysmorphism, hypoplastic nails/phalanges, and growth retardation. * **Amiodarone:** Can cause fetal **goiter or hypothyroidism** due to its high iodine content, but it is not the "classic" answer for general teratogenicity questions unless thyroid issues are mentioned. **High-Yield Clinical Pearls for NEET-PG:** 1. **Valproate** has the highest risk of major malformations among all antiepileptics. 2. **Warfarin** causes Fetal Warfarin Syndrome (stippled epiphyses and nasal hypoplasia); **Heparin** is the preferred anticoagulant in pregnancy. 3. **Isotretinoin** is the most potent human teratogen (causes CNS, cardiac, and craniofacial defects); strict contraception is mandatory. 4. **Thalidomide** causes Phocomelia (seal-like limbs). 5. **ACE Inhibitors** cause renal dysgenesis and oligohydramnios in the 2nd/3rd trimesters.

Practice by Chapter

Principles of Clinical Pharmacology

Practice Questions

Therapeutic Drug Monitoring

Practice Questions

Drug Toxicity and Overdose

Practice Questions

Antidotes and Their Applications

Practice Questions

Management of Drug Poisoning

Practice Questions

Drug-Induced Liver Injury

Practice Questions

Drug-Induced Kidney Injury

Practice Questions

Drug-Induced Blood Dyscrasias

Practice Questions

Drug-Induced QT Prolongation

Practice Questions

Pharmacovigilance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free